Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

Go back to Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) Delayed: 26.38 --0 (-0%)
Previous Close $26.38    52 Week High $5.17 
Open $26.38    52 Week Low $0.94 
Day High $26.38    P/E N/A 
Day Low $26.38    EPS $0.00 
Volume 3,161